Submit Manuscript  

Article Details


Oncolytic Viruses: The Best is Yet to Come

[ Vol. 18 , Issue. 2 ]

Author(s):

Chantal G. Lemay, Brian A. Keller, Robert E. Edge, Masato Abei and John C. Bell*Pages 109-123 (15)

Abstract:


Oncolytic viruses are a promising anti-cancer platform, achieving significant pre-clinical and clinical milestones in recent years. A full arsenal of selective, safe, and effective viruses has been developed with some emerging pre-clinical research focusing on optimizing these therapies in the face of remaining challenges, both in the bloodstream and in the tumour microenvironment. Herein we discuss the recent progress in pre-clinical virotherapy research to address these challenges, with special focus on innovative strategies that seek to complement the current strengths of virotherapy, ensuring an optimal multi-faceted attack on cancer. This review highlights the research areas that we believe provide the most potential to increase the efficacy of this exciting biotherapy platform: cell carriers, tumour vascular destruction, microenvironment modulation, combination therapies, and virus-mediated anti-tumour immune responses.

Keywords:

Cancer therapy, combination therapy, immunity, oncolytic viruses, tumour microenvironment, virotherapy.

Affiliation:

Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON

Graphical Abstract:



Read Full-Text article